---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-24-000070"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2024-10-22T23:59:59+00:00"
generated_at: "2026-05-30T11:36:48.782644+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Akebia signs multi-year supply agreement with leading dialysis org for Vafseo access

## Summary
- Contract with a leading kidney care provider serving >200,000 patients at thousands of U.S. dialysis centers.
- Vafseo (vadadustat) expected to be available in the U.S. in January 2025.
- CMS granted TDAPA reimbursement for Vafseo starting January 1, 2025, and issued a HCPCS billing code.
- Vafseo received FDA approval in March 2024 for anemia due to CKD in adults on dialysis for at least 3 months.
- Agreement enables physicians to prescribe Vafseo as clinically appropriate; commercial launch priority.

## SEC filing metadata
- accession: 0001517022-24-000070
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2024-10-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000070/0001517022-24-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000070/akba-20241022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-24-000070
- JSON: https://secwatch.observer/filing/0001517022-24-000070.json
- Plain text: https://secwatch.observer/filing/0001517022-24-000070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.